Sign In
Buy TARA
$4.22
-0.120 (-2.76%)
At Close: Jun 03, 2026
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts
01:22am, Friday, 16'th Jan 2026
Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are covering the company, MarketBeat Ratings reports. On
Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12:25am, Thursday, 15'th Jan 2026
Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
07:00am, Monday, 12'th Jan 2026
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 07'th Jan 2026
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages
01:11am, Monday, 22'nd Dec 2025
Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are presently covering the company, Marketbeat Rat
Protara Announces Closing of $75 Million Public Offering
04:05pm, Monday, 08'th Dec 2025
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare
Protara Announces Pricing of $75 Million Public Offering
10:03pm, Thursday, 04'th Dec 2025
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare
Protara Announces Proposed Public Offering
04:15pm, Thursday, 04'th Dec 2025
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare
Protara Therapeutics: End Of 2025 Proving Eventful Indeed
07:30am, Thursday, 04'th Dec 2025
Protara Therapeutics (TARA) maintains strong momentum with TARA-002, showing durable, high complete response rates in NMIBC and promising efficacy in lymphatic malformations. TARA-002's 6-month comple
Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
08:00am, Wednesday, 03'rd Dec 2025
TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patients TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 1
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today
Protara Therapeutics, Inc. ( TARA ) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations November 19, 2025 8:30 AM EST Company Participants Justine
80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical success Clinical success achieved with one or two doses of TARA-002 in
